{"id":27030,"date":"2024-12-24T17:25:02","date_gmt":"2024-12-25T00:25:02","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=27030"},"modified":"2024-12-24T17:25:05","modified_gmt":"2024-12-25T00:25:05","slug":"ivig-for-neonatal-hemochromatosis-nh","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/","title":{"rendered":"IgIV para la hemocromatosis neonatal (NH)"},"content":{"rendered":"<p>La hemocromatosis neonatal (NH) es una afecci\u00f3n extremadamente rara y potencialmente mortal que da\u00f1a el h\u00edgado del feto en desarrollo. Los beb\u00e9s con hemocromatosis neonatal suelen nacer prematuramente (muy pronto) o tienen dificultades para crecer con normalidad en el \u00fatero durante el embarazo.&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-c917da260877cf76cc5679d2b992eea4\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga su dosis de IgIV: infusi\u00f3n en casa\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<p>Si no se trata, esta afecci\u00f3n puede provocar muerte fetal al final del embarazo o la muerte del reci\u00e9n nacido despu\u00e9s del nacimiento debido a una lesi\u00f3n hep\u00e1tica grave y a la acumulaci\u00f3n de hierro en el cuerpo.&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig\/\">Terapia con IgIV<\/a> Se ha introducido con \u00e9xito en\u00a0<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8245207\/\">mejorar los resultados<\/a> de la hemocromatosis neonatal y se puede utilizar como tratamiento prenatal (durante el embarazo) y postnatal (despu\u00e9s del parto).\u00a0<\/p>\n\n\n\n<p>Este art\u00edculo revisa los conceptos b\u00e1sicos de la hemocromatosis neonatal, c\u00f3mo se produce y c\u00f3mo la IgIV puede utilizarse como una nueva terapia para tratar a los reci\u00e9n nacidos diagnosticados con NH y mejorar la tasa de supervivencia del feto en mujeres embarazadas con antecedentes de NH en embarazos previos.&nbsp;&nbsp;<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#Neonatal_Hemochromatosis_Brief_Overview\" >Hemocromatosis neonatal: breve descripci\u00f3n general<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#Causes_of_Neonatal_Hemochromatosis\" >Causas de la hemocromatosis neonatal<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#Link_of_Maternal-Fetal_Alloimmunity_with_Neonatal_Hemochromatosis\" >V\u00ednculo entre la aloinmunidad materno-fetal y la hemocromatosis neonatal<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#How_Can_IVIG_Help_Manage_Neonatal_Hemochromatosis\" >\u00bfC\u00f3mo puede la IgIV ayudar a controlar la hemocromatosis neonatal?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#1_Use_of_IVIG_as_a_Prenatal_Treatment_During_Pregnancy\" >1. Uso de IgIV como tratamiento prenatal (durante el embarazo)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#2_Use_of_IVIG_as_a_Postnatal_Treatment_After_Childbirth\" >2. Uso de IgIV como tratamiento postnatal (despu\u00e9s del parto)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#What_Is_the_Typical_Dosage_of_IVIG_for_NH\" >\u00bfCu\u00e1l es la dosis t\u00edpica de IgIV para la NH?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#Takeaway\" >Llevar<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\" id=\"h-neonatal-hemochromatosis-brief-overview\"><span class=\"ez-toc-section\" id=\"Neonatal_Hemochromatosis_Brief_Overview\"><\/span><strong>Hemocromatosis neonatal: breve descripci\u00f3n general<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La hemocromatosis es una afecci\u00f3n que describe la acumulaci\u00f3n excesiva de hierro en el organismo. En adultos, suele ser gen\u00e9tica (conocida como hemocromatosis hereditaria) y progresa lentamente. Sin embargo, la hemocromatosis neonatal es una afecci\u00f3n inmunomediada que se presenta durante el embarazo (generalmente en el cuarto mes).&nbsp;&nbsp;<\/p>\n\n\n\n<p>El feto en el \u00fatero desarrolla una lesi\u00f3n hep\u00e1tica avanzada debido a la aloinmunidad materno-fetal, que en \u00faltima instancia conduce a la acumulaci\u00f3n de hierro en el cuerpo y otros \u00f3rganos como el p\u00e1ncreas, el coraz\u00f3n y las gl\u00e1ndulas endocrinas.<\/p>\n\n\n\n<p>Para entender el papel de la IgIV en el tratamiento de la NH, primero revisemos brevemente qu\u00e9 causa exactamente la hemocromatosis neonatal.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-causes-of-neonatal-hemochromatosis\"><span class=\"ez-toc-section\" id=\"Causes_of_Neonatal_Hemochromatosis\"><\/span><strong>Causas de la hemocromatosis neonatal <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Numerosas evidencias de investigaci\u00f3n indican que en el 95% de los casos, la hemocromatosis neonatal es causada por aloinmunidad materno-fetal, una condici\u00f3n denominada <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1473050221003554#:~:text=Gestational%20alloimmune%20liver%20disease%20(GALD,iron%20accumulation%20at%20various%20sites.\">enfermedad hep\u00e1tica aloinmune gestacional (GALD)<\/a>, en la que los anticuerpos maternos atacan las c\u00e9lulas del h\u00edgado del feto durante el embarazo.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-link-of-maternal-fetal-alloimmunity-with-neonatal-hemochromatosis\"><span class=\"ez-toc-section\" id=\"Link_of_Maternal-Fetal_Alloimmunity_with_Neonatal_Hemochromatosis\"><\/span><strong>V\u00ednculo entre la aloinmunidad materno-fetal y la hemocromatosis neonatal<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>En un embarazo saludable, el sistema inmunol\u00f3gico de la madre produce anticuerpos IgG (anticuerpos maternos) que viajan a trav\u00e9s de la placenta para proteger al feto de infecciones.&nbsp;<\/p>\n\n\n\n<p>En algunos casos, estos anticuerpos maternos, en lugar de proteger al feto (beb\u00e9), identifican err\u00f3neamente las c\u00e9lulas fetales como &quot;extra\u00f1as&quot; y comienzan a atacarlas, causando da\u00f1o fetal. Esto se conoce como &quot;aloinmunidad materno-fetal&quot;.&nbsp;<\/p>\n\n\n\n<p>En la GALD (que es la causa subyacente de la NH), los anticuerpos maternos atacan espec\u00edficamente a las c\u00e9lulas hep\u00e1ticas del feto (hepatocitos) durante el embarazo, lo que finalmente causa da\u00f1o o lesi\u00f3n hep\u00e1tica. Este da\u00f1o provoca la acumulaci\u00f3n de hierro en el organismo del feto, lo que provoca s\u00edntomas de hemocromatosis neonatal.&nbsp;<\/p>\n\n\n\n<p>En pocas palabras, la NH es el resultado del ataque del sistema inmunol\u00f3gico de la madre al h\u00edgado del beb\u00e9 durante el embarazo debido a la GALD.<\/p>\n\n\n\n<p>Se estima que si su embarazo anterior termina en NH o su primer hijo nace con hemocromatosis neonatal, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8245207\/\">tiene aproximadamente una probabilidad de 90%<\/a> que su pr\u00f3ximo hijo tendr\u00e1 la misma condici\u00f3n.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Por lo tanto, se recomiendan tratamientos prenatales y postnatales para asegurar el nacimiento de un beb\u00e9 sano y mejorar la tasa de supervivencia de los reci\u00e9n nacidos con hemocromatosis neonatal (NH) sin requerir trasplantes de h\u00edgado.&nbsp;&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-166ea12744ce62962bfb963cc3582a35\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia para el copago de IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Empezar<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-can-ivig-help-manage-neonatal-hemochromatosis\"><span class=\"ez-toc-section\" id=\"How_Can_IVIG_Help_Manage_Neonatal_Hemochromatosis\"><\/span><strong>\u00bfC\u00f3mo puede la IgIV ayudar a controlar la hemocromatosis neonatal?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Se ha demostrado que la terapia con IgIV mejora el resultado de la NH cuando se utiliza como tratamiento prenatal y posnatal.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-1-use-of-ivig-as-a-prenatal-treatment-during-pregnancy\"><span class=\"ez-toc-section\" id=\"1_Use_of_IVIG_as_a_Prenatal_Treatment_During_Pregnancy\"><\/span>1. <strong>Uso de IgIV como tratamiento prenatal (durante el embarazo)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>El tratamiento con IgIV puede prevenir la recurrencia de la NH durante el embarazo. Por ejemplo, una <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S221491122200039X\">informe de caso<\/a> Una mujer de 32 a\u00f1os con antecedentes de NH en embarazos previos dio a luz un beb\u00e9 sano despu\u00e9s de recibir terapia con IgIV (en una dosis de 1 mg\/kg) semanalmente en el tercer trimestre hasta el final del embarazo.&nbsp;<\/p>\n\n\n\n<p>De manera similar, varios otros <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8245207\/\">estudios de caso<\/a> Se inform\u00f3 que recibir terapia con IgIV a las 14 semanas, 16 semanas y semanalmente desde la semana 18 hasta el final del embarazo puede <a href=\"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/pd.4232\">Prevenir la recurrencia de NH<\/a> y <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8245207\/\">aumentar la tasa de supervivencia del beb\u00e9<\/a>.&nbsp;<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-working-mechanism-of-ivig-as-a-prenatal-treatment\"><strong>Mecanismo de acci\u00f3n de la IgIV como tratamiento prenatal<\/strong><\/h4>\n\n\n\n<p>La terapia con IgIV como tratamiento prenatal puede ayudar a modular la respuesta inmunitaria de la madre durante el embarazo. Esto se logra mediante:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Neutralizar el efecto de los anticuerpos maternos que pasan de la madre al feto y da\u00f1an las c\u00e9lulas del h\u00edgado.\u00a0<\/li>\n\n\n\n<li>Reducir la inflamaci\u00f3n que da\u00f1a el h\u00edgado.<\/li>\n\n\n\n<li>Bloquear la activaci\u00f3n de la cascada del complemento (un componente del sistema inmunitario innato) que ataca a las c\u00e9lulas del h\u00edgado fetal.\u00a0<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-2-use-of-ivig-as-a-postnatal-treatment-after-childbirth\"><span class=\"ez-toc-section\" id=\"2_Use_of_IVIG_as_a_Postnatal_Treatment_After_Childbirth\"><\/span>2. <strong>Uso de IgIV como tratamiento postnatal (despu\u00e9s del parto)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"236\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/baby-in-crib.jpg\" alt=\"Sleeping newborn baby in crib\" class=\"wp-image-27033\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/baby-in-crib.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/baby-in-crib-300x169.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/baby-in-crib-86x48.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/baby-in-crib-167x94.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/baby-in-crib-280x157.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/baby-in-crib-370x208.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p>En reci\u00e9n nacidos con diagn\u00f3stico de NH, la IgIV puede utilizarse como parte de su plan de tratamiento para prevenir un mayor da\u00f1o hep\u00e1tico y reducir la necesidad de un trasplante de h\u00edgado. Estudios recientes demuestran que la terapia con IgIV puede bloquear la acci\u00f3n de los anticuerpos e interferir con la activaci\u00f3n de la cascada del complemento para prevenir la insuficiencia hep\u00e1tica grave en lactantes con NH.<\/p>\n\n\n\n<p>Seg\u00fan los resultados de la investigaci\u00f3n, el resultado (tasa de supervivencia sin trasplante de h\u00edgado) mejor\u00f3 de <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0022347609003710\">17% a 75% en beb\u00e9s<\/a> tratados con exanguinotransfusi\u00f3n (TE) y cuatro dosis de IgIV. De manera similar, en otro estudio <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3940210\/\">informe de caso<\/a> De 50 lactantes con NH, cuando fueron tratados tempranamente con IgIV, su tasa de supervivencia sin trasplante de h\u00edgado aument\u00f3 en 80%.&nbsp;<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-working-mechanism-of-ivig-as-a-postnatal-treatment\"><strong>Mecanismo de acci\u00f3n de la IgIV como tratamiento postnatal<\/strong><\/h4>\n\n\n\n<p>Como tratamiento posnatal, la terapia con IgIV funciona para prevenir complicaciones como insuficiencia multiorg\u00e1nica, detener el da\u00f1o hep\u00e1tico continuo y mejorar las tasas de supervivencia de los beb\u00e9s.&nbsp;<\/p>\n\n\n\n<p>La tasa de incidencia y muertes disminuy\u00f3 dr\u00e1sticamente entre los neonatos con NH despu\u00e9s de la administraci\u00f3n de IgIV como terapia preventiva.&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-3f29093ebdd27103332508551b7b1c07\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tHabla con un especialista\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tAcerca de la asistencia para copagos\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-the-typical-dosage-of-ivig-for-nh\"><span class=\"ez-toc-section\" id=\"What_Is_the_Typical_Dosage_of_IVIG_for_NH\"><\/span><strong>\u00bfCu\u00e1l es la dosis t\u00edpica de IgIV para la NH?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La IgIV se administra por v\u00eda intravenosa en un entorno hospitalario durante varias horas. Seg\u00fan la literatura, la IgIV puede administrarse en dosis de 1 g\/kg a pacientes con hemocromatosis neonatal. Sin embargo, las dosis pueden ajustarse seg\u00fan la salud del paciente, el peso del reci\u00e9n nacido y la gravedad de la afecci\u00f3n.&nbsp;&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-takeaway\"><span class=\"ez-toc-section\" id=\"Takeaway\"><\/span><strong>Llevar<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>En resumen, la hemocromatosis neonatal se puede controlar eficazmente con tratamiento prenatal e inyecci\u00f3n de IgIV posnatal temprana, ya que disminuye la gravedad de los s\u00edntomas, previene la insuficiencia hep\u00e1tica y evita la necesidad de un trasplante de h\u00edgado.&nbsp;<\/p>\n\n\n\n<p>Si usted o alguien que conoce ha perdido un beb\u00e9 prematuramente debido a hemocromatosis neonatal o tiene un mayor riesgo de recurrencia de la NH, el tratamiento con IgIV puede ayudar a controlar esta afecci\u00f3n. El diagn\u00f3stico temprano de la NH y la administraci\u00f3n de IgIV a reci\u00e9n nacidos con NH pueden lograr resultados positivos para las familias afectadas.<\/p>","protected":false},"excerpt":{"rendered":"<p>La hemocromatosis neonatal (NH) es una afecci\u00f3n extremadamente rara y potencialmente mortal que da\u00f1a el h\u00edgado del feto en desarrollo. Los beb\u00e9s con hemocromatosis neonatal suelen nacer prematuramente (muy pronto) o tienen dificultades para crecer con normalidad en el \u00fatero durante el embarazo.\u00a0<\/p>","protected":false},"author":25,"featured_media":27031,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[7],"tags":[31],"class_list":["post-27030","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ivig","tag-dr-mark-alfonso"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IVIG for Neonatal Hemochromatosis (NH) - AmeriPharma\u00ae Specialty Care<\/title>\n<meta name=\"description\" content=\"Learn how IVIG improves survival and prevents recurrence in neonatal hemochromatosis, which causes severe liver damage in newborns.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IVIG for Neonatal Hemochromatosis (NH) - AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"og:description\" content=\"Learn how IVIG improves survival and prevents recurrence in neonatal hemochromatosis, which causes severe liver damage in newborns.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-25T00:25:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-25T00:25:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Mark Alfonso, PharmD, BCMTMS\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Mark Alfonso, PharmD, BCMTMS\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-neonatal-hemochromatosis-nh\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-neonatal-hemochromatosis-nh\\\/\"},\"author\":{\"name\":\"Dr. Mark Alfonso, PharmD, BCMTMS\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/91fbbfa457730010998bc804c0467310\"},\"headline\":\"IVIG for Neonatal Hemochromatosis (NH)\",\"datePublished\":\"2024-12-25T00:25:02+00:00\",\"dateModified\":\"2024-12-25T00:25:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-neonatal-hemochromatosis-nh\\\/\"},\"wordCount\":1019,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-neonatal-hemochromatosis-nh\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/infant.jpg\",\"keywords\":[\"Dr. Mark Alfonso\"],\"articleSection\":[\"IVIG\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-neonatal-hemochromatosis-nh\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-neonatal-hemochromatosis-nh\\\/\",\"name\":\"IVIG for Neonatal Hemochromatosis (NH) - AmeriPharma\u00ae Specialty Care\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-neonatal-hemochromatosis-nh\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-neonatal-hemochromatosis-nh\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/infant.jpg\",\"datePublished\":\"2024-12-25T00:25:02+00:00\",\"dateModified\":\"2024-12-25T00:25:05+00:00\",\"description\":\"Learn how IVIG improves survival and prevents recurrence in neonatal hemochromatosis, which causes severe liver damage in newborns.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-neonatal-hemochromatosis-nh\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-neonatal-hemochromatosis-nh\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-neonatal-hemochromatosis-nh\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/infant.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/infant.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Newborn Asian baby girl with neonatal hemochromatosis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-neonatal-hemochromatosis-nh\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IVIG for Neonatal Hemochromatosis (NH)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/91fbbfa457730010998bc804c0467310\",\"name\":\"Dr. Mark Alfonso, PharmD, BCMTMS\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"caption\":\"Dr. Mark Alfonso, PharmD, BCMTMS\"},\"description\":\"Dr. Mark Alfonso, PharmD was born and raised in Pueblo, CO. He received his pharmacy degree from the University of Colorado School of Pharmacy at the Anschutz Medical Campus in 2010. He was board certified in medication therapy management in 2022. The most rewarding part of his job is helping to answer patient questions and concerns. His areas of expertise are community pharmacy and medication therapy management. In his free time, he enjoys reading and running.\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/mark-alfonso\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IgIV para la hemocromatosis neonatal (NH) - AmeriPharma\u00ae Atenci\u00f3n especializada","description":"Aprenda c\u00f3mo la IgIV mejora la supervivencia y previene la recurrencia de la hemocromatosis neonatal, que causa da\u00f1o hep\u00e1tico grave en los reci\u00e9n nacidos.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/","og_locale":"es_MX","og_type":"article","og_title":"IVIG for Neonatal Hemochromatosis (NH) - AmeriPharma\u00ae Specialty Care","og_description":"Learn how IVIG improves survival and prevents recurrence in neonatal hemochromatosis, which causes severe liver damage in newborns.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2024-12-25T00:25:02+00:00","article_modified_time":"2024-12-25T00:25:05+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg","type":"image\/jpeg"}],"author":"Dr. Mark Alfonso, PharmD, BCMTMS","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Mark Alfonso, PharmD, BCMTMS","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/"},"author":{"name":"Dr. Mark Alfonso, PharmD, BCMTMS","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/91fbbfa457730010998bc804c0467310"},"headline":"IVIG for Neonatal Hemochromatosis (NH)","datePublished":"2024-12-25T00:25:02+00:00","dateModified":"2024-12-25T00:25:05+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/"},"wordCount":1019,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg","keywords":["Dr. Mark Alfonso"],"articleSection":["IVIG"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/","url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/","name":"IgIV para la hemocromatosis neonatal (NH) - AmeriPharma\u00ae Atenci\u00f3n especializada","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg","datePublished":"2024-12-25T00:25:02+00:00","dateModified":"2024-12-25T00:25:05+00:00","description":"Aprenda c\u00f3mo la IgIV mejora la supervivencia y previene la recurrencia de la hemocromatosis neonatal, que causa da\u00f1o hep\u00e1tico grave en los reci\u00e9n nacidos.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg","width":1280,"height":853,"caption":"Newborn Asian baby girl with neonatal hemochromatosis"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-neonatal-hemochromatosis-nh\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/es\/"},{"@type":"ListItem","position":2,"name":"IVIG for Neonatal Hemochromatosis (NH)"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/#website","url":"https:\/\/ameripharmaspecialty.com\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/91fbbfa457730010998bc804c0467310","name":"Dr. Mark Alfonso, PharmD, BCMTMS","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","caption":"Dr. Mark Alfonso, PharmD, BCMTMS"},"description":"El Dr. Mark Alfonso, doctor en farmacia, naci\u00f3 y creci\u00f3 en Pueblo, Colorado. Obtuvo su t\u00edtulo en farmacia en la Facultad de Farmacia de la Universidad de Colorado, en el Campus M\u00e9dico Anschutz, en 2010. Obtuvo su certificaci\u00f3n en gesti\u00f3n de terapias farmacol\u00f3gicas en 2022. Lo m\u00e1s gratificante de su trabajo es ayudar a responder las preguntas e inquietudes de los pacientes. Sus \u00e1reas de especializaci\u00f3n son la farmacia comunitaria y la gesti\u00f3n de terapias farmacol\u00f3gicas. En su tiempo libre, disfruta de la lectura y correr.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Mark Alfonso, PharmD, BCMTMS","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"},"uagb_comment_info":0,"uagb_excerpt":"Neonatal hemochromatosis (NH) is an extremely rare and life-threatening condition that causes damage to the liver of a developing fetus. Babies with neonatal hemochromatosis are often born prematurely (very early) or struggle to grow normally in the womb during pregnancy.\u00a0","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/12\/infant.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Mark Alfonso, PharmD, BCMTMS","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/ivig\/\" rel=\"category tag\">IVIG<\/a>","rttpg_excerpt":"Neonatal hemochromatosis (NH) is an extremely rare and life-threatening condition that causes damage to the liver of a developing fetus. Babies with neonatal hemochromatosis are often born prematurely (very early) or struggle to grow normally in the womb during pregnancy.\u00a0","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=27030"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27030\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/27031"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=27030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=27030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=27030"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}